CN108377643B - 使用超小纳米粒子通过铁死亡诱导营养素剥夺癌细胞的细胞死亡的治疗方法 - Google Patents

使用超小纳米粒子通过铁死亡诱导营养素剥夺癌细胞的细胞死亡的治疗方法 Download PDF

Info

Publication number
CN108377643B
CN108377643B CN201680035303.4A CN201680035303A CN108377643B CN 108377643 B CN108377643 B CN 108377643B CN 201680035303 A CN201680035303 A CN 201680035303A CN 108377643 B CN108377643 B CN 108377643B
Authority
CN
China
Prior art keywords
tumor
cells
nanoparticles
iron
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680035303.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN108377643A (zh
Inventor
米歇尔·S·布拉德伯里
乌尔里希·维斯纳
M·奥韦尔霍尔策
H·谢尔
马凯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell University
Memorial Sloan Kettering Cancer Center
Original Assignee
Cornell University
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell University, Memorial Sloan Kettering Cancer Center filed Critical Cornell University
Priority to CN202111011162.1A priority Critical patent/CN113559279A/zh
Publication of CN108377643A publication Critical patent/CN108377643A/zh
Application granted granted Critical
Publication of CN108377643B publication Critical patent/CN108377643B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ceramic Engineering (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201680035303.4A 2015-05-29 2016-05-26 使用超小纳米粒子通过铁死亡诱导营养素剥夺癌细胞的细胞死亡的治疗方法 Active CN108377643B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111011162.1A CN113559279A (zh) 2015-05-29 2016-05-26 使用超小纳米粒子通过铁死亡诱导营养素剥夺癌细胞的细胞死亡的治疗方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562168636P 2015-05-29 2015-05-29
US62/168,636 2015-05-29
US201662280960P 2016-01-20 2016-01-20
US62/280,960 2016-01-20
PCT/US2016/034351 WO2016196201A1 (en) 2015-05-29 2016-05-26 Methods of treatment using ultrasmall nanoparticles to induce cell death of nutrient-deprived cancer cells via ferroptosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202111011162.1A Division CN113559279A (zh) 2015-05-29 2016-05-26 使用超小纳米粒子通过铁死亡诱导营养素剥夺癌细胞的细胞死亡的治疗方法

Publications (2)

Publication Number Publication Date
CN108377643A CN108377643A (zh) 2018-08-07
CN108377643B true CN108377643B (zh) 2021-09-21

Family

ID=56134596

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680035303.4A Active CN108377643B (zh) 2015-05-29 2016-05-26 使用超小纳米粒子通过铁死亡诱导营养素剥夺癌细胞的细胞死亡的治疗方法
CN202111011162.1A Pending CN113559279A (zh) 2015-05-29 2016-05-26 使用超小纳米粒子通过铁死亡诱导营养素剥夺癌细胞的细胞死亡的治疗方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202111011162.1A Pending CN113559279A (zh) 2015-05-29 2016-05-26 使用超小纳米粒子通过铁死亡诱导营养素剥夺癌细胞的细胞死亡的治疗方法

Country Status (10)

Country Link
US (3) US10736972B2 (https=)
EP (1) EP3302568B1 (https=)
JP (2) JP6974178B2 (https=)
KR (1) KR102730833B1 (https=)
CN (2) CN108377643B (https=)
AU (1) AU2016271040A1 (https=)
BR (1) BR112017024328A2 (https=)
CA (1) CA2985126A1 (https=)
HK (1) HK1253536A1 (https=)
WO (1) WO2016196201A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12161734B2 (en) 2009-07-02 2024-12-10 Sloan-Kettering Institute For Cancer Research Multimodal silica-based nanoparticles
DK3223013T3 (en) 2009-07-02 2019-04-15 Sloan Kettering Inst Cancer Res FLUORESCING SILICA-BASED NANOPARTICLES
CA2900363C (en) 2013-03-15 2023-10-10 Sloan-Kettering Institute For Cancer Research Multimodal silica-based nanoparticles
EP3148591B1 (en) 2014-05-29 2020-03-11 Memorial Sloan Kettering Cancer Center Nanoparticle drug conjugates
US10736972B2 (en) 2015-05-29 2020-08-11 Memorial Sloan Kettering Cancer Center Methods of treatment using ultrasmall nanoparticles to induce cell death of nutrient-deprived cancer cells via ferroptosis
WO2017189961A1 (en) 2016-04-29 2017-11-02 Memorial Sloan Kettering Cancer Center Compositions and methods for targeted particle penetration, distribution, and response in malignant brain tumors
EP3630089A4 (en) * 2017-05-24 2021-06-09 Ferro Therapeutics, Inc. PROCEDURE FOR CANCER THERAPY
WO2018217528A1 (en) * 2017-05-25 2018-11-29 Memorial Sloan Kettering Cancer Center Ultrasmall nanoparticles labeled with zirconium-89 and methods thereof
EP3645739A4 (en) * 2017-06-28 2021-07-14 The Regents of the University of California METHODS AND COMPOSITIONS FOR TREATMENT OF MELANOMA
US20200383943A1 (en) * 2017-12-04 2020-12-10 Memorial Sloan Kettering Cancer Center Methods of cancer treatment via regulated ferroptosis
US20210074995A1 (en) 2018-01-31 2021-03-11 Lg Chem, Ltd. Negative electrode active material, negative electrode including the same and lithium secondary battery including the same
JP7348906B2 (ja) 2018-02-28 2023-09-21 フェロ セラピューティクス， インコーポレイテッド フェロトーシス誘導活性を有する化合物およびそれらの使用方法
WO2019200343A1 (en) * 2018-04-13 2019-10-17 The Wistar Institute Of Anatomy And Biology S6k2 blockade perturbs redox balance and fatty acid metabolism, leading to oxidative cell death in mapk inhibitor resistant cancers
US12268742B2 (en) 2018-05-02 2025-04-08 Memorial Sloan Kettering Cancer Center Nanotherapeutic systems and methods using particle-driven photodynamic therapy (PDT)
WO2020077361A1 (en) * 2018-10-12 2020-04-16 The General Hospital Corporation Compounds and methods of their use
US12201956B2 (en) 2018-10-16 2025-01-21 Pharma In Silica Laboratories Inc. Tunable process for silica capsules/spheres preparation and their use
US20220193275A1 (en) * 2018-12-17 2022-06-23 Memorial Sloan Kettering Cancer Center Inducing favorable effects on tumor microenvironment via administration of nanoparticle compositions
US11040964B2 (en) 2019-02-27 2021-06-22 Ferro Therapeutics, Inc. Compounds and methods of use
WO2022093800A2 (en) 2020-10-27 2022-05-05 Elucida Oncology, Inc. Carrier particle-drug conjugates, self-immolative linkers, and uses thereof
CN112274495B (zh) * 2020-10-31 2022-05-03 郑州大学 一种h2o2自供型过氧化钙负载姜黄素纳米粒的制备方法及其应用
US20240285543A1 (en) * 2021-06-21 2024-08-29 Memorial Sloan-Kettering Cancer Center Nanoparticle-mediated enhancement of immunotherapy to promote ferroptosis-induced cytotoxicity and antitumor immune responses
WO2023023288A1 (en) * 2021-08-19 2023-02-23 Arpeggio Biosciences, Inc. Small molecule modulators of ferroptosis
US11541116B1 (en) 2022-01-07 2023-01-03 Kojin Therapeutics, Inc. Methods and compositions for inducing ferroptosis in vivo
CN115120595B (zh) * 2022-08-02 2023-06-30 广西医科大学第一附属医院 Liproxstatin-1在制备防治白血病的药物中的应用和其药物组合物
CN116270624A (zh) * 2023-02-14 2023-06-23 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） Tubastatin A的新应用
WO2025198008A1 (ja) * 2024-03-22 2025-09-25 公益財団法人がん研究会 フェロトーシス誘導促進剤
CN118879871B (zh) * 2024-09-27 2025-05-30 中国人民解放军总医院第三医学中心 一种肾癌预后标志物tymp及tymp抑制剂的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102713612A (zh) * 2009-07-02 2012-10-03 斯隆-凯特林癌症研究院 基于二氧化硅的荧光纳米颗粒
WO2014011973A2 (en) * 2012-07-13 2014-01-16 The Trustees Of Columbia University In The City Of New York Quinazolinone-based oncogenic-ras-selective lethal compounds and their use

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870791A (en) 1972-04-24 1975-03-11 Heskel M Haddad Solid state ophthalmic medication delivery method
US3867519A (en) 1972-04-27 1975-02-18 Alza Corp Bioerodible drug delivery device
US4051842A (en) 1975-09-15 1977-10-04 International Medical Corporation Electrode and interfacing pad for electrical physiological systems
DE2626348C3 (de) 1976-06-11 1980-01-31 Siemens Ag, 1000 Berlin Und 8000 Muenchen Implantierbare Dosiereinrichtung
US4136177A (en) 1977-01-31 1979-01-23 American Home Products Corp. Xanthan gum therapeutic compositions
US4255415A (en) 1978-11-22 1981-03-10 Schering Corporation Polyvinyl alcohol ophthalmic gel
US4383529A (en) 1980-11-03 1983-05-17 Wescor, Inc. Iontophoretic electrode device, method and gel insert
US4931279A (en) 1985-08-16 1990-06-05 Bausch & Lomb Incorporated Sustained release formulation containing an ion-exchange resin
US4688506A (en) 1985-09-03 1987-08-25 Breems Martinus Van Boat sail control system
US4788603A (en) 1985-10-19 1988-11-29 Fuji Photo Film Co., Ltd. Camera for sequentially photographing a subject using a reference optical system and a telescopic optical system
US4812409A (en) 1986-01-31 1989-03-14 Eastman Kodak Company Hydrolyzable fluorescent substrates and analytical determinations using same
US4713224A (en) 1986-03-31 1987-12-15 The Boc Group, Inc. One-step process for purifying an inert gas
US4810636A (en) 1986-12-09 1989-03-07 Miles Inc. Chromogenic acridinone enzyme substrates
US4774339A (en) 1987-08-10 1988-09-27 Molecular Probes, Inc. Chemically reactive dipyrrometheneboron difluoride dyes
US5274113A (en) 1991-11-01 1993-12-28 Molecular Probes, Inc. Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates
US5433896A (en) 1994-05-20 1995-07-18 Molecular Probes, Inc. Dibenzopyrrometheneboron difluoride dyes
US5248782A (en) 1990-12-18 1993-09-28 Molecular Probes, Inc. Long wavelength heteroaryl-substituted dipyrrometheneboron difluoride dyes
US5187288A (en) 1991-05-22 1993-02-16 Molecular Probes, Inc. Ethenyl-substituted dipyrrometheneboron difluoride dyes and their synthesis
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US5830912A (en) 1996-11-15 1998-11-03 Molecular Probes, Inc. Derivatives of 6,8-difluoro-7-hydroxycoumarin
CA2299471C (en) * 1997-08-15 2007-12-18 Cephalon Inc. Combination of tyrosine kinase inhibitor and chemical castration to treat prostate cancer
GB2330907A (en) 1997-10-28 1999-05-05 Applied Imaging Int Ltd A karyotyper and methods for producing karyotypes
ATE239801T1 (de) 1998-01-22 2003-05-15 Luminex Corp Mikropartikel mit multiplen fluoreszenz-signalen
US6254852B1 (en) 1999-07-16 2001-07-03 Dupont Pharmaceuticals Company Porous inorganic targeted ultrasound contrast agents
US7279150B2 (en) 2002-01-24 2007-10-09 Barnes-Jewish Hospital Chelating agents with lipophilic carriers
WO2003066066A1 (en) 2002-02-01 2003-08-14 Vanderbilt University Targeted drug delivery methods
US8620410B2 (en) 2002-03-12 2013-12-31 Beth Israel Deaconess Medical Center Multi-channel medical imaging system
US20040101822A1 (en) 2002-11-26 2004-05-27 Ulrich Wiesner Fluorescent silica-based nanoparticles
WO2004108902A2 (en) 2003-06-04 2004-12-16 Visen Medical, Inc. Biocompatible fluorescent silicon nanoparticles
WO2006042233A1 (en) 2004-10-08 2006-04-20 The Cleveland Clinic Foundation Medical imaging using quantum dots
US7653427B2 (en) 2004-11-12 2010-01-26 Intra-Medical Imaging LLC Method and instrument for minimally invasive sentinel lymph node location and biopsy
AU2006339072A1 (en) 2005-03-14 2007-10-25 Board Of Regents Of The University Of Texas System Bioactive FUS1 peptides and nanoparticle-polypeptide complexes
WO2006099445A2 (en) 2005-03-14 2006-09-21 Massachusetts Institute Of Technology Nanocells for diagnosis and treatment of diseases and disorders
US8084001B2 (en) 2005-05-02 2011-12-27 Cornell Research Foundation, Inc. Photoluminescent silica-based sensors and methods of use
US7601355B2 (en) 2005-06-01 2009-10-13 Northwestern University Compositions and methods for altering immune function
JP2008546804A (ja) 2005-06-24 2008-12-25 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 造影剤として用いるためのリガンドの放射性標識ペグ化
FR2888753B1 (fr) 2005-07-21 2008-04-04 Commissariat Energie Atomique Vecteur cible avec fonction d'imagerie activable
WO2007136413A2 (en) 2005-12-22 2007-11-29 Visen Medical, Inc. Biocompatible fluorescent metal oxide nanoparticles
WO2008044138A1 (en) 2006-10-12 2008-04-17 Syddansk Universitet Optical nanosensor for detection of reactive oxygen species
WO2008049118A2 (en) 2006-10-19 2008-04-24 The General Hospital Corporation Apparatus and method for obtaining and providing imaging information associated with at least one portion of a sample and effecting such portion(s)
US7902332B2 (en) 2006-11-30 2011-03-08 General Electric Company Fluorine-labeled compounds
WO2008073856A2 (en) 2006-12-08 2008-06-19 Massachusetts Institute Of Technology Delivery of nanoparticles and/or agents to cells
US8239008B2 (en) 2007-04-13 2012-08-07 Ethicon Endo-Surgery, Inc. Sentinel node identification using fluorescent nanoparticles
EP1995327A1 (en) 2007-05-21 2008-11-26 Humboldt Universität zu Berlin Probe for detecting a particular nucleic acid sequence
WO2009029870A2 (en) 2007-08-31 2009-03-05 Hybrid Silica Technologies, Inc. Peg-coated core-shell silica nanoparticles and methods of manufacture and use
DE102007052517A1 (de) 2007-10-29 2009-04-30 Autoimmun Diagnostika Gmbh ELISPOT-Verfahren mit zwei Filtersystemen
WO2009064964A2 (en) 2007-11-15 2009-05-22 The University Of California Switchable nano-vehicle delivery systems, and methods for making and using them
WO2009085218A1 (en) 2007-12-21 2009-07-09 President And Fellows Of Harvard College Sub-diffraction limit image resolution in three dimensions
WO2010091294A2 (en) 2009-02-05 2010-08-12 The Regents Of The University Of California New targeted antimicrobial moieties
ES2700870T3 (es) 2009-04-15 2019-02-19 Univ Cornell Nanopartículas de sílice fluorescentes mejoradas a través de densificación de sílice
US9005575B2 (en) 2009-06-12 2015-04-14 Stc.Unm Arg-Gly-Asp-conjugated alpha-melanocyte stimulating hormone hybrid peptide for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same
US12161734B2 (en) 2009-07-02 2024-12-10 Sloan-Kettering Institute For Cancer Research Multimodal silica-based nanoparticles
US9238069B2 (en) * 2009-12-16 2016-01-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of sensitizing cancer cells to the cytotoxic effects of death receptor ligands in cancer treatment
IN2012DN05099A (https=) 2009-12-16 2015-10-09 Brigham & Womens Hospital
SI2528625T1 (sl) 2010-04-15 2013-11-29 Spirogen Sarl Pirolobenzodiazepini in njihovi konjugati
GB201121288D0 (en) 2011-12-12 2012-01-25 Univ Muenster Wilhelms Functionalised silicon nanoparticles
US9006987B2 (en) 2012-05-07 2015-04-14 Lighting Science Group, Inc. Wall-mountable luminaire and associated systems and methods
US10732115B2 (en) 2012-06-22 2020-08-04 Cornell University Mesoporous oxide nanoparticles and methods of making and using same
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
EP2959299B1 (en) 2013-02-20 2019-01-02 Cornell University Multilayer fluorescent nanoparticles and methods of making and using same
CA2900363C (en) 2013-03-15 2023-10-10 Sloan-Kettering Institute For Cancer Research Multimodal silica-based nanoparticles
US10986997B2 (en) 2013-12-31 2021-04-27 Memorial Sloan Kettering Cancer Center Systems, methods, and apparatus for multichannel imaging of fluorescent sources in real time
EP3148591B1 (en) 2014-05-29 2020-03-11 Memorial Sloan Kettering Cancer Center Nanoparticle drug conjugates
CA2954725A1 (en) 2014-07-25 2016-01-28 Northeastern University Biopolymer-nanoparticle composite implant for tumor cell tracking
EP3029032A1 (en) 2014-12-05 2016-06-08 Centre National de la Recherche Scientifique (CNRS) Bifunctional do2pa derivatives, chelates with metallic cations and use thereof
RU2017122621A (ru) 2014-12-15 2019-01-17 Мемориал Слоун Кеттеринг Кэнсер Сентр Циклические пептиды с улучшенной селективностью связывания с нервами, наночастицы, связанные с указанными циклическими пептидами, и их применение для визуализации нервной ткани in vivo в реальном времени
JP6869187B2 (ja) 2015-04-07 2021-05-12 メモリアル スローン ケタリング キャンサー センター ナノ粒子イムノコンジュゲート
US11291737B2 (en) 2015-05-04 2022-04-05 Cornell University Ultrasmall nanoparticles and methods of making and using same
US10736972B2 (en) 2015-05-29 2020-08-11 Memorial Sloan Kettering Cancer Center Methods of treatment using ultrasmall nanoparticles to induce cell death of nutrient-deprived cancer cells via ferroptosis
US20180296595A1 (en) 2015-09-11 2018-10-18 Memorial Sloan Kettering Cancer Center Methods and compositions for cancer treatment
US11660354B2 (en) 2016-11-30 2023-05-30 Memorial Sloan Kettering Cancer Center Inhibitor-functionalized ultrasmall nanoparticles and methods thereof
WO2018191316A1 (en) 2017-04-10 2018-10-18 Cornell University Sulfur- or heavy atom-containing nanoparticles, methods of making same, and uses thereof
JP7309198B2 (ja) 2017-05-19 2023-07-18 コーネル ユニバーシティー 機能性ナノ粒子及びそれを製造する方法並びに使用する方法
EP3630089A4 (en) 2017-05-24 2021-06-09 Ferro Therapeutics, Inc. PROCEDURE FOR CANCER THERAPY
WO2018217528A1 (en) 2017-05-25 2018-11-29 Memorial Sloan Kettering Cancer Center Ultrasmall nanoparticles labeled with zirconium-89 and methods thereof
EP3642599B1 (en) 2017-06-23 2025-01-08 Memorial Sloan-Kettering Cancer Center Method of imaging in vivo tissues using nanoparticles comprising a reference dye and a sensor dye.
US20200383943A1 (en) 2017-12-04 2020-12-10 Memorial Sloan Kettering Cancer Center Methods of cancer treatment via regulated ferroptosis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102713612A (zh) * 2009-07-02 2012-10-03 斯隆-凯特林癌症研究院 基于二氧化硅的荧光纳米颗粒
WO2014011973A2 (en) * 2012-07-13 2014-01-16 The Trustees Of Columbia University In The City Of New York Quinazolinone-based oncogenic-ras-selective lethal compounds and their use

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Antitumor activity of sorafenib-incorporated nanoparticles of dextran/poly(dl-lactide-co-glycolide) block copolymer;Kim, DH,et al.;《NANOSCALE RESEARCH LETTERS》;20120101;第7卷;第1-6页 *
Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe;Phillips, E,et al.;《SCIENCE TRANSLATIONAL MEDICINE》;20141029;第6卷(第260期);第1-8页 *
Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death;Dixon, S,et al.;《CELL》;20120524;第149卷(第5期);第1060–1072页 *
Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma;Benezra, M, et al.;《JOURNAL OF CLINICAL INVESTIGATION》;20110613;第121卷(第7期);第2768-2780页 *
Sorafenib Induces Ferroptosis in Human Cancer Cell Lines Originating from Different Solid Tumors;Lachaier, E,et al.;《ANTICANCER RESEARCH》;20141101;第34卷(第11期);第6417-6422页 *
Ultrasmall Integrin-Targeted Silica Nanoparticles Modulate Signaling Events and Cellular Processes in a Concentration-Dependent Manner;Benezra, M ,et al.;《SMALL》;20141203;第11卷(第14期);第1721-1732页 *

Also Published As

Publication number Publication date
JP6974178B2 (ja) 2021-12-01
EP3302568A1 (en) 2018-04-11
AU2016271040A1 (en) 2017-11-23
KR102730833B1 (ko) 2024-11-18
US11931425B2 (en) 2024-03-19
CN113559279A (zh) 2021-10-29
JP2018516249A (ja) 2018-06-21
JP7263485B2 (ja) 2023-04-24
BR112017024328A2 (pt) 2018-07-24
WO2016196201A1 (en) 2016-12-08
US20220118106A1 (en) 2022-04-21
CA2985126A1 (en) 2016-12-08
CN108377643A (zh) 2018-08-07
US20200316219A1 (en) 2020-10-08
EP3302568B1 (en) 2023-12-06
HK1253536A1 (zh) 2019-06-21
JP2022023210A (ja) 2022-02-07
US10736972B2 (en) 2020-08-11
US20180169264A1 (en) 2018-06-21
KR20180012299A (ko) 2018-02-05
US11246946B2 (en) 2022-02-15

Similar Documents

Publication Publication Date Title
CN108377643B (zh) 使用超小纳米粒子通过铁死亡诱导营养素剥夺癌细胞的细胞死亡的治疗方法
US20240408251A1 (en) Compositions and methods for targeted particle penetration, distribution, and response in malignant brain tumors
Yang et al. Hollow MnO2 as a tumor-microenvironment-responsive biodegradable nano-platform for combination therapy favoring antitumor immune responses
Bayford et al. Emerging applications of nanotechnology for diagnosis and therapy of disease: a review
Kim et al. Ultrasmall nanoparticles induce ferroptosis in nutrient-deprived cancer cells and suppress tumour growth
Anhorn et al. Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticles
Hu et al. Peptide mediated active targeting and intelligent particle size reduction-mediated enhanced penetrating of fabricated nanoparticles for triple-negative breast cancer treatment
Yuan et al. Highly sensitive imaging of tumor metastasis based on the targeting and polarization of M2-like macrophages
Wu et al. Peptide-functionalized nanoinhibitor restrains brain tumor growth by abrogating mesenchymal-epithelial transition factor (MET) signaling
Ekshyyan et al. Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma
Kim et al. SPARC-independent delivery of nab-paclitaxel without depleting tumor stroma in patient-derived pancreatic cancer xenografts
Gigliotti et al. Enhanced cytotoxic effect of camptothecin nanosponges in anaplastic thyroid cancer cells in vitro and in vivo on orthotopic xenograft tumors
Wang et al. Nanoparticulate delivery system targeted to tumor neovasculature for combined anticancer and antiangiogenesis therapy
Cao et al. Multifunctional hybrid hydrogel system enhanced the therapeutic efficacy of treatments for postoperative glioma
Rampado et al. Nanovectors design for theranostic applications in colorectal cancer
US20230054210A1 (en) Compositions and methods for nanoparticle-based drug delivery and imaging
Bhattarai et al. CXC chemokine receptor 4 (CXCR4) targeted gold nanoparticles potently enhance radiotherapy outcomes in breast cancer
US9784730B2 (en) Nanoparticle for targeting brain tumors and delivery of O6-benzylguanine
Yao et al. Enhance mitochondrial damage by nuclear export inhibition to suppress tumor growth and metastasis with increased antitumor properties of macrophages
Pickering et al. Convection-enhanced delivery of auristatin-conjugated layer-by-layer nanoparticles for glioblastoma treatment
Peraudeau et al. Combination of targeted therapies for colorectal cancer treatment
Ramachandran et al. A polymer-protein core–shell nanomedicine for inhibiting cancer migration followed by photo-triggered killing
Gu et al. Evaluation of intraductal delivery of poly (ethylene glycol)‐doxorubicin conjugate nanocarriers for the treatment of ductal carcinoma in situ (DCIS)‐like lesions in rats
Chen et al. Prominin‐1‐Specific binding peptide‐modified apoferritin nanoparticle carrying irinotecan as a novel radiosensitizer for colorectal cancer stem‐like cells
Chen et al. Doxorubicin-loaded PEG-CdTe QDs conjugated with anti-CXCR4 mAbs: a novel delivery system for extramedullary multiple myeloma treatment

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant